Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyAzapropazone
Identification
- Name
- Azapropazone
- Accession Number
- DB07402
- Type
- Small Molecule
- Groups
- Withdrawn
- Description
- Not Available
- Structure
Structure for DB07402 (Azapropazone)
- Synonyms
- Azapropazone
- International/Other Brands
- Rheumox (Amdipharm Mercury Company Limited)
- Categories
- Analgesics
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Antigout Preparations
- Antiinflammatory and Antirheumatic Products
- Antiinflammatory and Antirheumatic Products, Non-Steroids
- Central Nervous System Agents
- Musculo-Skeletal System
- Nephrotoxic agents
- Peripheral Nervous System Agents
- Renal Agents
- Sensory System Agents
- Triazines
- Uricosuric Agents
- UNII
- K2VOT966ZI
- CAS number
- 13539-59-8
- Weight
- Average: 298.3397
Monoisotopic: 298.14297584 - Chemical Formula
- C16H18N4O2
- InChI Key
- WOIIIUDZSOLAIW-NSHDSACASA-N
- InChI
- InChI=1S/C16H18N4O2/c1-5-6-11-14(21)19-13-9-10(2)7-8-12(13)17-16(18(3)4)20(19)15(11)22/h5,7-9,11H,1,6H2,2-4H3/t11-/m0/s1
- IUPAC Name
- (4S)-7-(dimethylamino)-12-methyl-4-(prop-2-en-1-yl)-2,6,8-triazatricyclo[7.4.0.0²,⁶]trideca-1(13),7,9,11-tetraene-3,5-dione
- SMILES
- [H][C@@]1(CC=C)C(=O)N2N(C1=O)C1=CC(C)=CC=C1N=C2N(C)C
Pharmacology
- Indication
- Not Available
- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group (4R)-limonene The risk or severity of adverse effects can be increased when Azapropazone is combined with (4R)-limonene. Investigational 16-Bromoepiandrosterone The risk or severity of adverse effects can be increased when Azapropazone is combined with 16-Bromoepiandrosterone. Investigational 19-norandrostenedione The risk or severity of adverse effects can be increased when Azapropazone is combined with 19-norandrostenedione. Experimental, Illicit 5-androstenedione The risk or severity of adverse effects can be increased when Azapropazone is combined with 5-androstenedione. Experimental, Illicit Abciximab The risk or severity of bleeding and hemorrhage can be increased when Azapropazone is combined with Abciximab. Approved Acebutolol Azapropazone may decrease the antihypertensive activities of Acebutolol. Approved, Investigational Aceclofenac The risk or severity of adverse effects can be increased when Azapropazone is combined with Aceclofenac. Approved, Investigational Acemetacin The risk or severity of adverse effects can be increased when Azapropazone is combined with Acemetacin. Approved, Experimental, Investigational Acenocoumarol Azapropazone may increase the anticoagulant activities of Acenocoumarol. Approved, Investigational Acetylsalicylic acid The risk or severity of adverse effects can be increased when Azapropazone is combined with Acetylsalicylic acid. Approved, Vet Approved Adapalene The risk or severity of adverse effects can be increased when Adapalene is combined with Azapropazone. Approved Alclofenac The risk or severity of adverse effects can be increased when Azapropazone is combined with Alclofenac. Approved, Withdrawn Alclometasone The risk or severity of adverse effects can be increased when Azapropazone is combined with Alclometasone. Approved Aldosterone The risk or severity of adverse effects can be increased when Azapropazone is combined with Aldosterone. Experimental, Investigational Alendronic acid The risk or severity of adverse effects can be increased when Azapropazone is combined with Alendronic acid. Approved Aliskiren Azapropazone may decrease the antihypertensive activities of Aliskiren. Approved, Investigational Alminoprofen The risk or severity of adverse effects can be increased when Azapropazone is combined with Alminoprofen. Experimental Alprenolol Azapropazone may decrease the antihypertensive activities of Alprenolol. Approved, Withdrawn Alprostadil The therapeutic efficacy of Alprostadil can be decreased when used in combination with Azapropazone. Approved, Investigational Alteplase The risk or severity of bleeding and hemorrhage can be increased when Azapropazone is combined with Alteplase. Approved Amcinonide The risk or severity of adverse effects can be increased when Azapropazone is combined with Amcinonide. Approved Amikacin The risk or severity of nephrotoxicity can be increased when Azapropazone is combined with Amikacin. Approved, Investigational, Vet Approved Amiloride Azapropazone may decrease the antihypertensive activities of Amiloride. Approved Aminosalicylic Acid The risk or severity of adverse effects can be increased when Azapropazone is combined with Aminosalicylic Acid. Approved Amlodipine The therapeutic efficacy of Amlodipine can be decreased when used in combination with Azapropazone. Approved Ancrod Azapropazone may increase the anticoagulant activities of Ancrod. Approved, Investigational Andrographolide The risk or severity of adverse effects can be increased when Andrographolide is combined with Azapropazone. Investigational Androstenedione The risk or severity of adverse effects can be increased when Azapropazone is combined with Androstenedione. Experimental, Illicit Anecortave The risk or severity of adverse effects can be increased when Azapropazone is combined with Anecortave. Investigational anecortave acetate The risk or severity of adverse effects can be increased when Azapropazone is combined with anecortave acetate. Investigational Anisodamine The risk or severity of adverse effects can be increased when Azapropazone is combined with Anisodamine. Investigational Antipyrine The risk or severity of adverse effects can be increased when Azapropazone is combined with Antipyrine. Approved, Investigational Antithrombin III human Azapropazone may increase the anticoagulant activities of Antithrombin III human. Approved Antrafenine The risk or severity of adverse effects can be increased when Azapropazone is combined with Antrafenine. Approved Apixaban Azapropazone may increase the anticoagulant activities of Apixaban. Approved Apocynin The risk or severity of adverse effects can be increased when Azapropazone is combined with Apocynin. Investigational Apramycin Azapropazone may decrease the excretion rate of Apramycin which could result in a higher serum level. Experimental, Vet Approved Apremilast The risk or severity of adverse effects can be increased when Apremilast is combined with Azapropazone. Approved, Investigational Arbekacin Azapropazone may decrease the excretion rate of Arbekacin which could result in a higher serum level. Approved, Investigational Ardeparin Azapropazone may increase the anticoagulant activities of Ardeparin. Approved, Investigational, Withdrawn Argatroban Azapropazone may increase the anticoagulant activities of Argatroban. Approved, Investigational Arotinolol Azapropazone may decrease the antihypertensive activities of Arotinolol. Investigational Asenapine Azapropazone may decrease the antihypertensive activities of Asenapine. Approved Atamestane The risk or severity of adverse effects can be increased when Azapropazone is combined with Atamestane. Investigational Atenolol Azapropazone may decrease the antihypertensive activities of Atenolol. Approved Azelastine The risk or severity of adverse effects can be increased when Azelastine is combined with Azapropazone. Approved Azficel-T The risk or severity of adverse effects can be increased when Azapropazone is combined with Azficel-T. Approved, Investigational Azilsartan medoxomil The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Azapropazone. Approved, Investigational Azosemide The therapeutic efficacy of Azosemide can be decreased when used in combination with Azapropazone. Investigational Bacitracin The risk or severity of nephrotoxicity can be increased when Azapropazone is combined with Bacitracin. Approved, Vet Approved Balsalazide The risk or severity of adverse effects can be increased when Azapropazone is combined with Balsalazide. Approved, Investigational Becaplermin Azapropazone may increase the anticoagulant activities of Becaplermin. Approved, Investigational Beclomethasone dipropionate The risk or severity of gastrointestinal irritation can be increased when Beclomethasone dipropionate is combined with Azapropazone. Approved, Investigational Befunolol Azapropazone may decrease the antihypertensive activities of Befunolol. Experimental Bekanamycin Azapropazone may decrease the excretion rate of Bekanamycin which could result in a higher serum level. Experimental Benazepril The risk or severity of adverse effects can be increased when Azapropazone is combined with Benazepril. Approved, Investigational Bendazac The risk or severity of adverse effects can be increased when Azapropazone is combined with Bendazac. Experimental Bendroflumethiazide The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Azapropazone. Approved Benorilate The risk or severity of adverse effects can be increased when Azapropazone is combined with Benorilate. Experimental Benoxaprofen The risk or severity of adverse effects can be increased when Benoxaprofen is combined with Azapropazone. Withdrawn Benzthiazide The therapeutic efficacy of Benzthiazide can be decreased when used in combination with Azapropazone. Approved Benzydamine The risk or severity of adverse effects can be increased when Azapropazone is combined with Benzydamine. Approved Bepridil The therapeutic efficacy of Bepridil can be decreased when used in combination with Azapropazone. Approved, Withdrawn Beraprost The therapeutic efficacy of Beraprost can be decreased when used in combination with Azapropazone. Investigational Betamethasone The risk or severity of adverse effects can be increased when Azapropazone is combined with Betamethasone. Approved, Vet Approved Betaxolol Azapropazone may decrease the antihypertensive activities of Betaxolol. Approved, Investigational Betrixaban The risk or severity of bleeding can be increased when Betrixaban is combined with Azapropazone. Approved, Investigational Bevantolol Azapropazone may decrease the antihypertensive activities of Bevantolol. Approved Bevonium The risk or severity of adverse effects can be increased when Azapropazone is combined with Bevonium. Experimental Bimatoprost The therapeutic efficacy of Bimatoprost can be decreased when used in combination with Azapropazone. Approved, Investigational Bisoprolol Azapropazone may decrease the antihypertensive activities of Bisoprolol. Approved Bivalirudin The risk or severity of bleeding and hemorrhage can be increased when Azapropazone is combined with Bivalirudin. Approved, Investigational Bopindolol Azapropazone may decrease the antihypertensive activities of Bopindolol. Approved Bromfenac The risk or severity of adverse effects can be increased when Azapropazone is combined with Bromfenac. Approved Bucillamine The risk or severity of adverse effects can be increased when Azapropazone is combined with Bucillamine. Investigational Bucindolol Azapropazone may decrease the antihypertensive activities of Bucindolol. Investigational Budesonide The risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Azapropazone. Approved Bufexamac The risk or severity of adverse effects can be increased when Azapropazone is combined with Bufexamac. Approved, Experimental Bufuralol Azapropazone may decrease the antihypertensive activities of Bufuralol. Experimental, Investigational Bumadizone The risk or severity of adverse effects can be increased when Azapropazone is combined with Bumadizone. Experimental Bumetanide The therapeutic efficacy of Bumetanide can be decreased when used in combination with Azapropazone. Approved Bupranolol Azapropazone may decrease the antihypertensive activities of Bupranolol. Approved Candesartan The risk or severity of adverse effects can be increased when Candesartan is combined with Azapropazone. Experimental Candesartan cilexetil The risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Azapropazone. Approved Candoxatril The risk or severity of adverse effects can be increased when Azapropazone is combined with Candoxatril. Experimental Capsaicin The risk or severity of adverse effects can be increased when Azapropazone is combined with Capsaicin. Approved Captopril The risk or severity of adverse effects can be increased when Azapropazone is combined with Captopril. Approved Carbaspirin calcium The risk or severity of adverse effects can be increased when Azapropazone is combined with Carbaspirin calcium. Experimental, Investigational Carboprost Tromethamine The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Azapropazone. Approved Carprofen The risk or severity of adverse effects can be increased when Azapropazone is combined with Carprofen. Approved, Vet Approved, Withdrawn Carteolol Azapropazone may decrease the antihypertensive activities of Carteolol. Approved Carvedilol Azapropazone may decrease the antihypertensive activities of Carvedilol. Approved, Investigational Castanospermine The risk or severity of adverse effects can be increased when Castanospermine is combined with Azapropazone. Experimental Celecoxib The risk or severity of adverse effects can be increased when Azapropazone is combined with Celecoxib. Approved, Investigational Celiprolol Azapropazone may decrease the antihypertensive activities of Celiprolol. Approved, Investigational Certoparin Azapropazone may increase the anticoagulant activities of Certoparin. Approved, Investigational Chloroquine The risk or severity of adverse effects can be increased when Chloroquine is combined with Azapropazone. Approved, Investigational, Vet Approved Chlorothiazide The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Azapropazone. Approved, Vet Approved Chlorphenesin The risk or severity of adverse effects can be increased when Azapropazone is combined with Chlorphenesin. Approved, Vet Approved, Withdrawn Chlorthalidone The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Azapropazone. Approved Cholestyramine Cholestyramine can cause a decrease in the absorption of Azapropazone resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Choline magnesium trisalicylate The risk or severity of adverse effects can be increased when Azapropazone is combined with Choline magnesium trisalicylate. Approved Ciclesonide The risk or severity of adverse effects can be increased when Azapropazone is combined with Ciclesonide. Approved, Investigational Cilazapril The risk or severity of adverse effects can be increased when Azapropazone is combined with Cilazapril. Approved Cimicoxib The risk or severity of adverse effects can be increased when Azapropazone is combined with Cimicoxib. Investigational Cinoxacin Azapropazone may increase the neuroexcitatory activities of Cinoxacin. Approved, Investigational, Withdrawn Ciprofloxacin Azapropazone may increase the neuroexcitatory activities of Ciprofloxacin. Approved, Investigational Cisplatin The risk or severity of adverse effects can be increased when Azapropazone is combined with Cisplatin. Approved Clobetasol The risk or severity of adverse effects can be increased when Azapropazone is combined with Clobetasol. Approved, Investigational Clobetasol propionate The risk or severity of adverse effects can be increased when Azapropazone is combined with Clobetasol propionate. Approved Clobetasone The risk or severity of adverse effects can be increased when Azapropazone is combined with Clobetasone. Approved Clocortolone The risk or severity of adverse effects can be increased when Azapropazone is combined with Clocortolone. Approved Clodronic Acid The risk or severity of adverse effects can be increased when Azapropazone is combined with Clodronic Acid. Approved, Investigational, Vet Approved Clonixin The risk or severity of adverse effects can be increased when Azapropazone is combined with Clonixin. Approved Cloprostenol The therapeutic efficacy of Cloprostenol can be decreased when used in combination with Azapropazone. Vet Approved Cloranolol Azapropazone may decrease the antihypertensive activities of Cloranolol. Experimental Colesevelam Colesevelam can cause a decrease in the absorption of Azapropazone resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Colestipol Colestipol can cause a decrease in the absorption of Azapropazone resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Cortexolone 17α-propionate The risk or severity of adverse effects can be increased when Azapropazone is combined with Cortexolone 17α-propionate. Investigational Corticosterone The risk or severity of adverse effects can be increased when Azapropazone is combined with Corticosterone. Experimental Cortisone acetate The risk or severity of adverse effects can be increased when Azapropazone is combined with Cortisone acetate. Approved, Investigational Curcumin The risk or severity of adverse effects can be increased when Azapropazone is combined with Curcumin. Approved, Investigational Cyclopenthiazide The therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Azapropazone. Experimental Cyclosporine The risk or severity of renal failure and hypertension can be increased when Azapropazone is combined with Cyclosporine. Approved, Investigational, Vet Approved Dabigatran etexilate Azapropazone may increase the anticoagulant activities of Dabigatran etexilate. Approved Dalteparin Azapropazone may increase the anticoagulant activities of Dalteparin. Approved Danaparoid Azapropazone may increase the anticoagulant activities of Danaparoid. Approved, Withdrawn Darexaban Azapropazone may increase the anticoagulant activities of Darexaban. Investigational Deferasirox The risk or severity of adverse effects can be increased when Azapropazone is combined with Deferasirox. Approved, Investigational Deflazacort The risk or severity of adverse effects can be increased when Azapropazone is combined with Deflazacort. Approved, Investigational Delapril The risk or severity of adverse effects can be increased when Azapropazone is combined with Delapril. Investigational Desipramine Azapropazone may decrease the antihypertensive activities of Desipramine. Approved, Investigational Desirudin Azapropazone may increase the anticoagulant activities of Desirudin. Approved Desmopressin The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Azapropazone is combined with Desmopressin. Approved Desonide The risk or severity of adverse effects can be increased when Azapropazone is combined with Desonide. Approved, Investigational Desoximetasone The risk or severity of adverse effects can be increased when Azapropazone is combined with Desoximetasone. Approved Desoxycorticosterone acetate The risk or severity of adverse effects can be increased when Azapropazone is combined with Desoxycorticosterone acetate. Approved Desoxycorticosterone Pivalate The risk or severity of adverse effects can be increased when Azapropazone is combined with Desoxycorticosterone Pivalate. Experimental, Vet Approved Dexamethasone The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Azapropazone. Approved, Investigational, Vet Approved Dexamethasone isonicotinate The risk or severity of adverse effects can be increased when Azapropazone is combined with Dexamethasone isonicotinate. Vet Approved Dexibuprofen The risk or severity of adverse effects can be increased when Azapropazone is combined with Dexibuprofen. Approved, Investigational Dexketoprofen The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Azapropazone. Approved, Investigational Dexniguldipine The therapeutic efficacy of Dexniguldipine can be decreased when used in combination with Azapropazone. Experimental Dextran Azapropazone may increase the anticoagulant activities of Dextran. Approved, Investigational, Vet Approved Dibekacin Azapropazone may decrease the excretion rate of Dibekacin which could result in a higher serum level. Experimental Dibotermin alfa The risk or severity of adverse effects can be increased when Azapropazone is combined with Dibotermin alfa. Approved, Investigational Diclofenac The risk or severity of adverse effects can be increased when Diclofenac is combined with Azapropazone. Approved, Vet Approved Dicoumarol Azapropazone may increase the anticoagulant activities of Dicoumarol. Approved Difenpiramide The risk or severity of adverse effects can be increased when Azapropazone is combined with Difenpiramide. Experimental Diflorasone The risk or severity of adverse effects can be increased when Azapropazone is combined with Diflorasone. Approved Diflunisal The risk or severity of adverse effects can be increased when Azapropazone is combined with Diflunisal. Approved, Investigational Difluocortolone The risk or severity of adverse effects can be increased when Azapropazone is combined with Difluocortolone. Approved, Investigational, Withdrawn Difluprednate The risk or severity of adverse effects can be increased when Azapropazone is combined with Difluprednate. Approved Digoxin The serum concentration of Digoxin can be increased when it is combined with Azapropazone. Approved Dihydrostreptomycin Azapropazone may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level. Investigational, Vet Approved Diltiazem The therapeutic efficacy of Diltiazem can be decreased when used in combination with Azapropazone. Approved, Investigational Dinoprost The therapeutic efficacy of Dinoprost can be decreased when used in combination with Azapropazone. Investigational Dinoprost Tromethamine The therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Azapropazone. Approved, Vet Approved Dinoprostone The therapeutic efficacy of Dinoprostone can be decreased when used in combination with Azapropazone. Approved Doxazosin The therapeutic efficacy of Doxazosin can be decreased when used in combination with Azapropazone. Approved Drospirenone Azapropazone may increase the hyperkalemic activities of Drospirenone. Approved Droxicam The risk or severity of adverse effects can be increased when Azapropazone is combined with Droxicam. Withdrawn Duvelisib The risk or severity of adverse effects can be increased when Azapropazone is combined with Duvelisib. Investigational E-6201 The risk or severity of adverse effects can be increased when Azapropazone is combined with E-6201. Investigational Edetic Acid Azapropazone may increase the anticoagulant activities of Edetic Acid. Approved, Vet Approved Edoxaban Azapropazone may increase the anticoagulant activities of Edoxaban. Approved Efonidipine The therapeutic efficacy of Efonidipine can be decreased when used in combination with Azapropazone. Approved, Investigational Enalapril The risk or severity of adverse effects can be increased when Azapropazone is combined with Enalapril. Approved, Vet Approved Enalaprilat The risk or severity of adverse effects can be increased when Azapropazone is combined with Enalaprilat. Approved Enoxacin Azapropazone may increase the neuroexcitatory activities of Enoxacin. Approved, Investigational Enoxaparin Azapropazone may increase the anticoagulant activities of Enoxaparin. Approved Enprostil The therapeutic efficacy of Enprostil can be decreased when used in combination with Azapropazone. Experimental Epanolol Azapropazone may decrease the antihypertensive activities of Epanolol. Experimental Epirizole The risk or severity of adverse effects can be increased when Azapropazone is combined with Epirizole. Approved Epitizide The therapeutic efficacy of Epitizide can be decreased when used in combination with Azapropazone. Experimental Eplerenone Azapropazone may decrease the antihypertensive activities of Eplerenone. Approved Epoprostenol The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Azapropazone. Approved Eprosartan The risk or severity of adverse effects can be increased when Eprosartan is combined with Azapropazone. Approved Equilenin The risk or severity of adverse effects can be increased when Azapropazone is combined with Equilenin. Experimental Equilin The risk or severity of adverse effects can be increased when Azapropazone is combined with Equilin. Approved Esatenolol Azapropazone may decrease the antihypertensive activities of Esatenolol. Experimental Esmolol Azapropazone may decrease the antihypertensive activities of Esmolol. Approved Estrone The risk or severity of adverse effects can be increased when Azapropazone is combined with Estrone. Approved Estrone sulfate The risk or severity of adverse effects can be increased when Azapropazone is combined with Estrone sulfate. Approved Etacrynic acid The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Azapropazone. Approved, Investigational Ethenzamide The risk or severity of adverse effects can be increased when Azapropazone is combined with Ethenzamide. Experimental Ethyl biscoumacetate Azapropazone may increase the anticoagulant activities of Ethyl biscoumacetate. Withdrawn Etidronic acid The risk or severity of adverse effects can be increased when Azapropazone is combined with Etidronic acid. Approved Etodolac The risk or severity of adverse effects can be increased when Azapropazone is combined with Etodolac. Approved, Investigational, Vet Approved Etofenamate The risk or severity of adverse effects can be increased when Azapropazone is combined with Etofenamate. Approved, Investigational Etoricoxib The risk or severity of adverse effects can be increased when Azapropazone is combined with Etoricoxib. Approved, Investigational Evening primrose oil The risk or severity of adverse effects can be increased when Azapropazone is combined with Evening primrose oil. Investigational, Nutraceutical Exisulind The risk or severity of adverse effects can be increased when Exisulind is combined with Azapropazone. Investigational Felbinac The risk or severity of adverse effects can be increased when Azapropazone is combined with Felbinac. Experimental Felodipine The therapeutic efficacy of Felodipine can be decreased when used in combination with Azapropazone. Approved, Investigational Fenbufen The risk or severity of adverse effects can be increased when Azapropazone is combined with Fenbufen. Approved Fenoprofen The risk or severity of adverse effects can be increased when Azapropazone is combined with Fenoprofen. Approved Fenprostalene The therapeutic efficacy of Fenprostalene can be decreased when used in combination with Azapropazone. Vet Approved Fentiazac The risk or severity of adverse effects can be increased when Azapropazone is combined with Fentiazac. Experimental Feprazone The risk or severity of adverse effects can be increased when Azapropazone is combined with Feprazone. Experimental Ferulic acid Azapropazone may increase the anticoagulant activities of Ferulic acid. Experimental Fimasartan The risk or severity of adverse effects can be increased when Fimasartan is combined with Azapropazone. Approved, Investigational Fleroxacin Azapropazone may increase the neuroexcitatory activities of Fleroxacin. Approved Floctafenine The risk or severity of adverse effects can be increased when Floctafenine is combined with Azapropazone. Approved, Withdrawn Fluasterone The risk or severity of adverse effects can be increased when Azapropazone is combined with Fluasterone. Investigational Fludrocortisone The risk or severity of adverse effects can be increased when Azapropazone is combined with Fludrocortisone. Approved, Investigational Fluindione Azapropazone may increase the anticoagulant activities of Fluindione. Approved, Investigational Flumequine Azapropazone may increase the neuroexcitatory activities of Flumequine. Withdrawn Flumethasone The risk or severity of adverse effects can be increased when Azapropazone is combined with Flumethasone. Approved, Vet Approved Flunisolide The risk or severity of adverse effects can be increased when Azapropazone is combined with Flunisolide. Approved, Investigational Flunixin The risk or severity of adverse effects can be increased when Azapropazone is combined with Flunixin. Vet Approved Flunoxaprofen The risk or severity of adverse effects can be increased when Azapropazone is combined with Flunoxaprofen. Experimental Fluocinolone Acetonide The risk or severity of adverse effects can be increased when Azapropazone is combined with Fluocinolone Acetonide. Approved, Investigational, Vet Approved Fluocinonide The risk or severity of adverse effects can be increased when Azapropazone is combined with Fluocinonide. Approved, Investigational Fluocortolone The risk or severity of adverse effects can be increased when Azapropazone is combined with Fluocortolone. Approved, Withdrawn Fluorometholone The risk or severity of adverse effects can be increased when Azapropazone is combined with Fluorometholone. Approved, Investigational Fluprednidene The risk or severity of adverse effects can be increased when Azapropazone is combined with Fluprednidene. Approved, Withdrawn Fluprednisolone The risk or severity of adverse effects can be increased when Azapropazone is combined with Fluprednisolone. Approved Fluprostenol The therapeutic efficacy of Fluprostenol can be decreased when used in combination with Azapropazone. Vet Approved Flurandrenolide The risk or severity of adverse effects can be increased when Azapropazone is combined with Flurandrenolide. Approved Flurbiprofen The risk or severity of adverse effects can be increased when Azapropazone is combined with Flurbiprofen. Approved, Investigational Fluticasone The risk or severity of adverse effects can be increased when Azapropazone is combined with Fluticasone. Approved, Experimental, Investigational Fluticasone furoate The risk or severity of adverse effects can be increased when Azapropazone is combined with Fluticasone furoate. Approved Fluticasone propionate The risk or severity of gastrointestinal irritation can be increased when Fluticasone propionate is combined with Azapropazone. Approved Folic Acid The therapeutic efficacy of Folic Acid can be decreased when used in combination with Azapropazone. Approved, Nutraceutical, Vet Approved Fondaparinux Azapropazone may increase the anticoagulant activities of Fondaparinux sodium. Approved, Investigational Forasartan The risk or severity of adverse effects can be increased when Forasartan is combined with Azapropazone. Experimental Formestane The risk or severity of adverse effects can be increased when Azapropazone is combined with Formestane. Approved, Investigational, Withdrawn Fosinopril The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Azapropazone is combined with Fosinopril. Approved Framycetin Azapropazone may decrease the excretion rate of Framycetin which could result in a higher serum level. Approved Furosemide The therapeutic efficacy of Furosemide can be decreased when used in combination with Azapropazone. Approved, Vet Approved Gabexate Azapropazone may increase the anticoagulant activities of Gabexate. Investigational Garenoxacin Azapropazone may increase the neuroexcitatory activities of Garenoxacin. Investigational Gatifloxacin Azapropazone may increase the neuroexcitatory activities of Gatifloxacin. Approved, Investigational Gemeprost The therapeutic efficacy of Gemeprost can be decreased when used in combination with Azapropazone. Approved, Withdrawn Gemifloxacin Azapropazone may increase the neuroexcitatory activities of Gemifloxacin. Approved, Investigational Geneticin Azapropazone may decrease the excretion rate of Geneticin which could result in a higher serum level. Experimental Gentamicin Azapropazone may decrease the excretion rate of Gentamicin which could result in a higher serum level. Approved, Vet Approved GENTAMICIN C1A Azapropazone may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level. Experimental Ginseng The risk or severity of adverse effects can be increased when Azapropazone is combined with Ginseng. Approved, Investigational, Nutraceutical Glipizide The protein binding of Glipizide can be decreased when combined with Azapropazone. Approved, Investigational Glyburide The protein binding of Glyburide can be decreased when combined with Azapropazone. Approved Grepafloxacin Azapropazone may increase the neuroexcitatory activities of Grepafloxacin. Approved, Investigational, Withdrawn Guacetisal The risk or severity of adverse effects can be increased when Azapropazone is combined with Guacetisal. Experimental Guanfacine The therapeutic efficacy of Guanfacine can be decreased when used in combination with Azapropazone. Approved, Investigational Halcinonide The risk or severity of adverse effects can be increased when Azapropazone is combined with Halcinonide. Approved, Investigational, Withdrawn Haloperidol The risk or severity of adverse effects can be increased when Azapropazone is combined with Haloperidol. Approved HE3286 The risk or severity of adverse effects can be increased when Azapropazone is combined with HE3286. Investigational Heparin Azapropazone may increase the anticoagulant activities of Heparin. Approved, Investigational Higenamine The risk or severity of adverse effects can be increased when Azapropazone is combined with Higenamine. Investigational Hydralazine Azapropazone may decrease the antihypertensive activities of Hydralazine. Approved Hydrochlorothiazide The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Azapropazone. Approved, Vet Approved Hydrocortisone The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Azapropazone. Approved, Vet Approved Hydrocortisone acetate The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone acetate is combined with Azapropazone. Approved, Vet Approved Hydrocortisone butyrate The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone butyrate is combined with Azapropazone. Approved, Vet Approved Hydroflumethiazide The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Azapropazone. Approved, Investigational Hygromycin B Azapropazone may decrease the excretion rate of Hygromycin B which could result in a higher serum level. Vet Approved Ibandronate The risk or severity of gastrointestinal bleeding can be increased when Azapropazone is combined with Ibandronate. Approved, Investigational Ibuprofen The risk or severity of adverse effects can be increased when Ibuprofen is combined with Azapropazone. Approved Ibuproxam The risk or severity of adverse effects can be increased when Azapropazone is combined with Ibuproxam. Withdrawn Icatibant The risk or severity of adverse effects can be increased when Icatibant is combined with Azapropazone. Approved, Investigational Icosapent The risk or severity of adverse effects can be increased when Azapropazone is combined with Icosapent. Approved, Nutraceutical Idraparinux Azapropazone may increase the anticoagulant activities of Idraparinux. Investigational Iloprost The therapeutic efficacy of Iloprost can be decreased when used in combination with Azapropazone. Approved, Investigational Imidapril The risk or severity of adverse effects can be increased when Azapropazone is combined with Imidapril. Investigational Imidazole salicylate The risk or severity of adverse effects can be increased when Azapropazone is combined with Imidazole salicylate. Experimental Indapamide The therapeutic efficacy of Indapamide can be decreased when used in combination with Azapropazone. Approved Indenolol Azapropazone may decrease the antihypertensive activities of Indenolol. Withdrawn Indobufen The risk or severity of adverse effects can be increased when Azapropazone is combined with Indobufen. Investigational Indomethacin The risk or severity of adverse effects can be increased when Azapropazone is combined with Indomethacin. Approved, Investigational Indoprofen The risk or severity of adverse effects can be increased when Azapropazone is combined with Indoprofen. Withdrawn Irbesartan The risk or severity of adverse effects can be increased when Irbesartan is combined with Azapropazone. Approved, Investigational Isepamicin Azapropazone may decrease the excretion rate of Isepamicin which could result in a higher serum level. Experimental Isoxicam The risk or severity of adverse effects can be increased when Azapropazone is combined with Isoxicam. Withdrawn Isradipine The therapeutic efficacy of Isradipine can be decreased when used in combination with Azapropazone. Approved, Investigational Istaroxime The risk or severity of adverse effects can be increased when Azapropazone is combined with Istaroxime. Investigational Kanamycin Azapropazone may decrease the excretion rate of Kanamycin which could result in a higher serum level. Approved, Investigational, Vet Approved Kebuzone The risk or severity of adverse effects can be increased when Azapropazone is combined with Kebuzone. Experimental Ketoprofen The risk or severity of adverse effects can be increased when Azapropazone is combined with Ketoprofen. Approved, Vet Approved Ketorolac The risk or severity of adverse effects can be increased when Ketorolac is combined with Azapropazone. Approved Labetalol Azapropazone may decrease the antihypertensive activities of Labetalol. Approved Lacidipine The therapeutic efficacy of Lacidipine can be decreased when used in combination with Azapropazone. Approved, Investigational Landiolol Azapropazone may decrease the antihypertensive activities of Landiolol. Investigational Latanoprost The therapeutic efficacy of Latanoprost can be decreased when used in combination with Azapropazone. Approved, Investigational Latanoprostene Bunod The therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Azapropazone. Approved, Investigational Leflunomide The risk or severity of adverse effects can be increased when Leflunomide is combined with Azapropazone. Approved, Investigational Lepirudin Azapropazone may increase the anticoagulant activities of Lepirudin. Approved Lercanidipine The therapeutic efficacy of Lercanidipine can be decreased when used in combination with Azapropazone. Approved, Investigational Letaxaban Azapropazone may increase the anticoagulant activities of Letaxaban. Investigational Levobetaxolol Azapropazone may decrease the antihypertensive activities of Levobetaxolol. Approved, Investigational Levobunolol Azapropazone may decrease the antihypertensive activities of Levobunolol. Approved Levofloxacin Azapropazone may increase the neuroexcitatory activities of Levofloxacin. Approved, Investigational Limaprost The therapeutic efficacy of Limaprost can be decreased when used in combination with Azapropazone. Approved, Investigational Lisinopril The risk or severity of adverse effects can be increased when Azapropazone is combined with Lisinopril. Approved, Investigational Lisofylline The risk or severity of adverse effects can be increased when Azapropazone is combined with Lisofylline. Investigational Lithium cation The serum concentration of Lithium can be increased when it is combined with Azapropazone. Experimental Lomefloxacin Azapropazone may increase the neuroexcitatory activities of Lomefloxacin. Approved, Investigational Lonazolac The risk or severity of adverse effects can be increased when Azapropazone is combined with Lonazolac. Experimental Lornoxicam The risk or severity of adverse effects can be increased when Azapropazone is combined with Lornoxicam. Approved, Investigational Losartan The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Azapropazone. Approved Loteprednol The risk or severity of adverse effects can be increased when Azapropazone is combined with Loteprednol. Approved Loxoprofen The risk or severity of adverse effects can be increased when Azapropazone is combined with Loxoprofen. Approved, Investigational Lubiprostone The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Azapropazone. Approved, Investigational Lumiracoxib The risk or severity of adverse effects can be increased when Azapropazone is combined with Lumiracoxib. Approved, Investigational Luprostiol The therapeutic efficacy of Luprostiol can be decreased when used in combination with Azapropazone. Vet Approved Magnesium salicylate The risk or severity of adverse effects can be increased when Azapropazone is combined with Magnesium salicylate. Approved Manidipine The therapeutic efficacy of Manidipine can be decreased when used in combination with Azapropazone. Approved, Investigational Masoprocol The risk or severity of adverse effects can be increased when Masoprocol is combined with Azapropazone. Approved, Investigational ME-609 The risk or severity of adverse effects can be increased when Azapropazone is combined with ME-609. Investigational Meclofenamic acid The risk or severity of adverse effects can be increased when Azapropazone is combined with Meclofenamic acid. Approved, Vet Approved Medrysone The risk or severity of adverse effects can be increased when Azapropazone is combined with Medrysone. Approved Mefenamic acid The risk or severity of adverse effects can be increased when Azapropazone is combined with Mefenamic acid. Approved Melagatran Azapropazone may increase the anticoagulant activities of Melagatran. Experimental Melengestrol The risk or severity of adverse effects can be increased when Azapropazone is combined with Melengestrol. Vet Approved Meloxicam The risk or severity of adverse effects can be increased when Azapropazone is combined with Meloxicam. Approved, Vet Approved Mepindolol Azapropazone may decrease the antihypertensive activities of Mepindolol. Experimental Mesalazine The risk or severity of adverse effects can be increased when Azapropazone is combined with Mesalazine. Approved Metamizole The risk or severity of adverse effects can be increased when Metamizole is combined with Azapropazone. Approved, Investigational, Withdrawn Methotrexate The serum concentration of Methotrexate can be increased when it is combined with Azapropazone. Approved Methyclothiazide The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Azapropazone. Approved Methylprednisolone The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Azapropazone. Approved, Vet Approved Metipranolol Azapropazone may decrease the antihypertensive activities of Metipranolol. Approved Metolazone The therapeutic efficacy of Metolazone can be decreased when used in combination with Azapropazone. Approved Metoprolol Azapropazone may decrease the antihypertensive activities of Metoprolol. Approved, Investigational Mibefradil The therapeutic efficacy of Mibefradil can be decreased when used in combination with Azapropazone. Investigational, Withdrawn Micronomicin Azapropazone may decrease the excretion rate of Micronomicin which could result in a higher serum level. Experimental Mifamurtide The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Azapropazone. Approved, Experimental Minoxidil The therapeutic efficacy of Minoxidil can be decreased when used in combination with Azapropazone. Approved, Investigational Misoprostol The therapeutic efficacy of Misoprostol can be decreased when used in combination with Azapropazone. Approved Mizoribine The risk or severity of adverse effects can be increased when Azapropazone is combined with Mizoribine. Investigational Moexipril The risk or severity of adverse effects can be increased when Azapropazone is combined with Moexipril. Approved Mofebutazone The risk or severity of adverse effects can be increased when Azapropazone is combined with Mofebutazone. Experimental Mometasone The risk or severity of adverse effects can be increased when Azapropazone is combined with Mometasone. Approved, Vet Approved Morniflumate The risk or severity of adverse effects can be increased when Morniflumate is combined with Azapropazone. Approved Moxifloxacin Azapropazone may increase the neuroexcitatory activities of Moxifloxacin. Approved, Investigational Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Azapropazone. Approved, Investigational Mycophenolic acid The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Azapropazone. Approved Nabumetone The risk or severity of adverse effects can be increased when Azapropazone is combined with Nabumetone. Approved Nadolol Azapropazone may decrease the antihypertensive activities of Nadolol. Approved Nadroparin Azapropazone may increase the anticoagulant activities of Nadroparin. Approved, Investigational Nafamostat Azapropazone may increase the anticoagulant activities of Nafamostat. Approved, Investigational Naftifine The risk or severity of adverse effects can be increased when Naftifine is combined with Azapropazone. Approved Naftopidil The therapeutic efficacy of Naftopidil can be decreased when used in combination with Azapropazone. Investigational Nalidixic Acid Azapropazone may increase the neuroexcitatory activities of Nalidixic Acid. Approved, Investigational Naproxen The risk or severity of adverse effects can be increased when Naproxen is combined with Azapropazone. Approved, Vet Approved NCX 1022 The risk or severity of adverse effects can be increased when Azapropazone is combined with NCX 1022. Investigational Neamine Azapropazone may decrease the excretion rate of Neamine which could result in a higher serum level. Experimental Nebivolol Azapropazone may decrease the antihypertensive activities of Nebivolol. Approved, Investigational Nemonoxacin Azapropazone may increase the neuroexcitatory activities of Nemonoxacin. Investigational Neomycin The risk or severity of nephrotoxicity can be increased when Azapropazone is combined with Neomycin. Approved, Vet Approved Nepafenac The risk or severity of adverse effects can be increased when Azapropazone is combined with Nepafenac. Approved, Investigational Netilmicin Azapropazone may decrease the excretion rate of Netilmicin which could result in a higher serum level. Approved, Investigational Nicardipine The therapeutic efficacy of Nicardipine can be decreased when used in combination with Azapropazone. Approved, Investigational Nifenazone The risk or severity of adverse effects can be increased when Azapropazone is combined with Nifenazone. Experimental Niflumic Acid The risk or severity of adverse effects can be increased when Azapropazone is combined with Niflumic Acid. Approved Niguldipine The therapeutic efficacy of Niguldipine can be decreased when used in combination with Azapropazone. Experimental Nilvadipine The therapeutic efficacy of Nilvadipine can be decreased when used in combination with Azapropazone. Approved, Investigational Nimesulide The risk or severity of adverse effects can be increased when Nimesulide is combined with Azapropazone. Approved, Investigational, Withdrawn Nimodipine The therapeutic efficacy of Nimodipine can be decreased when used in combination with Azapropazone. Approved, Investigational Nisoldipine The therapeutic efficacy of Nisoldipine can be decreased when used in combination with Azapropazone. Approved Nitrendipine The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Azapropazone. Approved, Investigational Nitroaspirin The risk or severity of adverse effects can be increased when Azapropazone is combined with Nitroaspirin. Investigational Norfloxacin Azapropazone may increase the neuroexcitatory activities of Norfloxacin. Approved Ofloxacin Azapropazone may increase the neuroexcitatory activities of Ofloxacin. Approved Oleoyl-estrone The risk or severity of adverse effects can be increased when Azapropazone is combined with Oleoyl-estrone. Investigational Olmesartan The risk or severity of adverse effects can be increased when Olmesartan is combined with Azapropazone. Approved, Investigational Olopatadine The risk or severity of adverse effects can be increased when Olopatadine is combined with Azapropazone. Approved Olsalazine Azapropazone may increase the nephrotoxic activities of Olsalazine. Approved Omacetaxine mepesuccinate The risk or severity of bleeding can be increased when Azapropazone is combined with Omacetaxine mepesuccinate. Approved, Investigational Omapatrilat The risk or severity of adverse effects can be increased when Azapropazone is combined with Omapatrilat. Investigational Orgotein The risk or severity of adverse effects can be increased when Azapropazone is combined with Orgotein. Vet Approved Otamixaban Azapropazone may increase the anticoagulant activities of Otamixaban. Investigational Oxaprozin The risk or severity of adverse effects can be increased when Azapropazone is combined with Oxaprozin. Approved Oxolinic acid Azapropazone may increase the neuroexcitatory activities of Oxolinic acid. Experimental Oxprenolol Azapropazone may decrease the antihypertensive activities of Oxprenolol. Approved Oxyphenbutazone The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Azapropazone. Approved, Withdrawn Palmidrol The risk or severity of adverse effects can be increased when Azapropazone is combined with Palmidrol. Experimental, Nutraceutical Pamidronate The risk or severity of adverse effects can be increased when Azapropazone is combined with Pamidronate. Approved Paramethasone The risk or severity of adverse effects can be increased when Azapropazone is combined with Paramethasone. Approved Parecoxib The risk or severity of adverse effects can be increased when Azapropazone is combined with Parecoxib. Approved Paromomycin The risk or severity of nephrotoxicity can be increased when Azapropazone is combined with Paromomycin. Approved, Investigational Parthenolide The risk or severity of adverse effects can be increased when Azapropazone is combined with Parthenolide. Approved, Investigational Pazufloxacin Azapropazone may increase the neuroexcitatory activities of Pazufloxacin. Investigational Pefloxacin Azapropazone may increase the neuroexcitatory activities of Pefloxacin. Approved Penbutolol Azapropazone may decrease the antihypertensive activities of Penbutolol. Approved, Investigational Pentaerythritol Tetranitrate Azapropazone may increase the anticoagulant activities of Pentaerythritol Tetranitrate. Approved Pentosan Polysulfate Azapropazone may increase the anticoagulant activities of Pentosan Polysulfate. Approved Perindopril The risk or severity of adverse effects can be increased when Azapropazone is combined with Perindopril. Approved Phenindione Azapropazone may increase the anticoagulant activities of Phenindione. Approved, Investigational Phenprocoumon Azapropazone may increase the anticoagulant activities of Phenprocoumon. Approved, Investigational Phenylbutazone The risk or severity of adverse effects can be increased when Azapropazone is combined with Phenylbutazone. Approved, Vet Approved Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Azapropazone. Approved, Investigational Pindolol Azapropazone may decrease the antihypertensive activities of Pindolol. Approved, Investigational Pipemidic acid Azapropazone may increase the neuroexcitatory activities of Pipemidic acid. Experimental Piretanide The therapeutic efficacy of Piretanide can be decreased when used in combination with Azapropazone. Approved Pirfenidone The risk or severity of adverse effects can be increased when Pirfenidone is combined with Azapropazone. Approved, Investigational Piromidic acid Azapropazone may increase the neuroexcitatory activities of Piromidic acid. Experimental Piroxicam The risk or severity of adverse effects can be increased when Azapropazone is combined with Piroxicam. Approved, Investigational Pirprofen The risk or severity of adverse effects can be increased when Azapropazone is combined with Pirprofen. Experimental Pitolisant The risk or severity of adverse effects can be increased when Azapropazone is combined with Pitolisant. Approved, Investigational Platelet Activating Factor Azapropazone may decrease the antihypertensive activities of Platelet Activating Factor. Experimental Plazomicin Azapropazone may decrease the excretion rate of Plazomicin which could result in a higher serum level. Approved, Investigational Polythiazide The therapeutic efficacy of Polythiazide can be decreased when used in combination with Azapropazone. Approved Pomalidomide The risk or severity of adverse effects can be increased when Azapropazone is combined with Pomalidomide. Approved Potassium Citrate Azapropazone may increase the anticoagulant activities of Potassium Citrate. Approved, Investigational, Vet Approved Practolol Azapropazone may decrease the antihypertensive activities of Practolol. Approved Pralatrexate The serum concentration of Pralatrexate can be increased when it is combined with Azapropazone. Approved, Investigational Pranoprofen The risk or severity of adverse effects can be increased when Azapropazone is combined with Pranoprofen. Experimental, Investigational Prasterone The risk or severity of adverse effects can be increased when Azapropazone is combined with Prasterone. Approved, Investigational, Nutraceutical Prasterone sulfate The risk or severity of adverse effects can be increased when Azapropazone is combined with Prasterone sulfate. Investigational Prednicarbate The risk or severity of adverse effects can be increased when Azapropazone is combined with Prednicarbate. Approved, Investigational Prednisolone The risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Azapropazone. Approved, Vet Approved Prednisone The risk or severity of adverse effects can be increased when Azapropazone is combined with Prednisone. Approved, Vet Approved Pregnenolone The risk or severity of adverse effects can be increased when Azapropazone is combined with Pregnenolone. Approved, Experimental, Investigational Probenecid The serum concentration of Azapropazone can be increased when it is combined with Probenecid. Approved, Investigational Proglumetacin The risk or severity of adverse effects can be increased when Azapropazone is combined with Proglumetacin. Experimental Propacetamol The risk or severity of adverse effects can be increased when Azapropazone is combined with Propacetamol. Approved, Investigational Propafenone Azapropazone may decrease the antihypertensive activities of Propafenone. Approved Propranolol Azapropazone may decrease the antihypertensive activities of Propranolol. Approved, Investigational Propyphenazone The risk or severity of adverse effects can be increased when Azapropazone is combined with Propyphenazone. Experimental Proquazone The risk or severity of adverse effects can be increased when Azapropazone is combined with Proquazone. Experimental Prostaglandin B2 The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Azapropazone. Experimental Prostaglandin G2 The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Azapropazone. Experimental Prostalene The therapeutic efficacy of Prostalene can be decreased when used in combination with Azapropazone. Vet Approved Protein C Azapropazone may increase the anticoagulant activities of Protein C. Approved Protein S human Azapropazone may increase the anticoagulant activities of Protein S human. Approved Protocatechualdehyde Azapropazone may increase the anticoagulant activities of Protocatechualdehyde. Approved Prulifloxacin Azapropazone may increase the neuroexcitatory activities of Prulifloxacin. Investigational PTC299 The risk or severity of adverse effects can be increased when PTC299 is combined with Azapropazone. Investigational Puromycin Azapropazone may decrease the excretion rate of Puromycin which could result in a higher serum level. Experimental Quinapril The risk or severity of adverse effects can be increased when Azapropazone is combined with Quinapril. Approved, Investigational Quinethazone The therapeutic efficacy of Quinethazone can be decreased when used in combination with Azapropazone. Approved Ramipril The risk or severity of adverse effects can be increased when Azapropazone is combined with Ramipril. Approved Rescinnamine The risk or severity of adverse effects can be increased when Azapropazone is combined with Rescinnamine. Approved Resveratrol The risk or severity of adverse effects can be increased when Azapropazone is combined with Resveratrol. Approved, Experimental, Investigational Reteplase The risk or severity of bleeding and hemorrhage can be increased when Azapropazone is combined with Reteplase. Approved, Investigational Reviparin Azapropazone may increase the anticoagulant activities of Reviparin. Approved, Investigational Ribostamycin Azapropazone may decrease the excretion rate of Ribostamycin which could result in a higher serum level. Approved, Investigational Rimexolone The risk or severity of adverse effects can be increased when Azapropazone is combined with Rimexolone. Approved Risedronate The risk or severity of adverse effects can be increased when Azapropazone is combined with Risedronate. Approved, Investigational Rivaroxaban Azapropazone may increase the anticoagulant activities of Rivaroxaban. Approved Rofecoxib The risk or severity of adverse effects can be increased when Azapropazone is combined with Rofecoxib. Approved, Investigational, Withdrawn Rosoxacin Azapropazone may increase the neuroexcitatory activities of Rosoxacin. Approved, Investigational Rufloxacin Azapropazone may increase the neuroexcitatory activities of Rufloxacin. Experimental Sacubitril The risk or severity of adverse effects can be increased when Sacubitril is combined with Azapropazone. Approved Salicylamide The risk or severity of adverse effects can be increased when Azapropazone is combined with Salicylamide. Approved Salicylic acid The risk or severity of adverse effects can be increased when Salicylic acid is combined with Azapropazone. Approved, Investigational, Vet Approved Salsalate The risk or severity of adverse effects can be increased when Azapropazone is combined with Salsalate. Approved Saprisartan The risk or severity of adverse effects can be increased when Saprisartan is combined with Azapropazone. Experimental Saralasin The risk or severity of adverse effects can be increased when Saralasin is combined with Azapropazone. Investigational Sarilumab Sarilumab may increase the immunosuppressive activities of Azapropazone. Approved, Investigational Seliciclib The risk or severity of adverse effects can be increased when Azapropazone is combined with Seliciclib. Investigational Semapimod The risk or severity of adverse effects can be increased when Azapropazone is combined with Semapimod. Investigational Seratrodast The risk or severity of adverse effects can be increased when Seratrodast is combined with Azapropazone. Approved Serrapeptase The risk or severity of adverse effects can be increased when Azapropazone is combined with Serrapeptase. Investigational Sisomicin Azapropazone may decrease the excretion rate of Sisomicin which could result in a higher serum level. Investigational Sitafloxacin Azapropazone may increase the neuroexcitatory activities of Sitafloxacin. Experimental, Investigational Sodium Citrate The risk or severity of bleeding and hemorrhage can be increased when Azapropazone is combined with Sodium Citrate. Approved, Investigational Sodium phosphate, monobasic The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Azapropazone. Approved Sotalol Azapropazone may decrease the antihypertensive activities of Sotalol. Approved Sparfloxacin Azapropazone may increase the neuroexcitatory activities of Sparfloxacin. Approved, Investigational Spirapril The risk or severity of adverse effects can be increased when Azapropazone is combined with Spirapril. Approved Spironolactone The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Azapropazone is combined with Spironolactone. Approved SRT501 The risk or severity of adverse effects can be increased when SRT501 is combined with Azapropazone. Investigational Streptomycin Azapropazone may decrease the excretion rate of Streptomycin which could result in a higher serum level. Approved, Vet Approved Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Azapropazone. Approved Sulindac The risk or severity of adverse effects can be increased when Sulindac is combined with Azapropazone. Approved, Investigational Sulodexide Azapropazone may increase the anticoagulant activities of Sulodexide. Approved, Investigational Sulprostone The therapeutic efficacy of Sulprostone can be decreased when used in combination with Azapropazone. Investigational Suprofen The risk or severity of adverse effects can be increased when Azapropazone is combined with Suprofen. Approved, Withdrawn Suxibuzone The risk or severity of adverse effects can be increased when Azapropazone is combined with Suxibuzone. Experimental Tacrolimus Azapropazone may increase the nephrotoxic activities of Tacrolimus. Approved, Investigational Tafluprost The therapeutic efficacy of Tafluprost can be decreased when used in combination with Azapropazone. Approved Talinolol Azapropazone may decrease the antihypertensive activities of Talinolol. Investigational Talniflumate The risk or severity of adverse effects can be increased when Talniflumate is combined with Azapropazone. Approved Tarenflurbil The risk or severity of adverse effects can be increased when Tarenflurbil is combined with Azapropazone. Investigational Tasosartan The risk or severity of adverse effects can be increased when Tasosartan is combined with Azapropazone. Approved Technetium Tc-99m etidronate The risk or severity of adverse effects can be increased when Azapropazone is combined with Technetium Tc-99m etidronate. Approved Technetium Tc-99m medronate The risk or severity of adverse effects can be increased when Azapropazone is combined with Technetium Tc-99m medronate. Approved Telmisartan The risk or severity of adverse effects can be increased when Telmisartan is combined with Azapropazone. Approved, Investigational Temafloxacin Azapropazone may increase the neuroexcitatory activities of Temafloxacin. Withdrawn Temocapril The risk or severity of adverse effects can be increased when Azapropazone is combined with Temocapril. Experimental, Investigational Tenecteplase The risk or severity of bleeding and hemorrhage can be increased when Azapropazone is combined with Tenecteplase. Approved Tenidap The risk or severity of adverse effects can be increased when Azapropazone is combined with Tenidap. Experimental Tenofovir disoproxil The risk or severity of adverse effects can be increased when Azapropazone is combined with Tenofovir disoproxil. Approved, Investigational Tenoxicam The risk or severity of adverse effects can be increased when Azapropazone is combined with Tenoxicam. Approved Tepoxalin The risk or severity of adverse effects can be increased when Azapropazone is combined with Tepoxalin. Vet Approved Terbutaline Azapropazone may decrease the antihypertensive activities of Terbutaline. Approved Teriflunomide The risk or severity of adverse effects can be increased when Azapropazone is combined with Teriflunomide. Approved Tertatolol Azapropazone may decrease the antihypertensive activities of Tertatolol. Experimental Tetrahydropalmatine The therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Azapropazone. Investigational Tiaprofenic acid The risk or severity of adverse effects can be increased when Azapropazone is combined with Tiaprofenic acid. Approved Tiludronic acid The risk or severity of adverse effects can be increased when Azapropazone is combined with Tiludronic acid. Approved, Investigational, Vet Approved Timolol Azapropazone may decrease the antihypertensive activities of Timolol. Approved Tinoridine The risk or severity of adverse effects can be increased when Azapropazone is combined with Tinoridine. Investigational Tixocortol The risk or severity of adverse effects can be increased when Azapropazone is combined with Tixocortol. Approved, Withdrawn Tobramycin Azapropazone may decrease the excretion rate of Tobramycin which could result in a higher serum level. Approved, Investigational Tolfenamic Acid The risk or severity of adverse effects can be increased when Azapropazone is combined with Tolfenamic Acid. Approved, Investigational Tolmetin The risk or severity of adverse effects can be increased when Azapropazone is combined with Tolmetin. Approved Torasemide The therapeutic efficacy of Torasemide can be decreased when used in combination with Azapropazone. Approved Trandolapril The risk or severity of adverse effects can be increased when Azapropazone is combined with Trandolapril. Approved Travoprost The therapeutic efficacy of Travoprost can be decreased when used in combination with Azapropazone. Approved Treprostinil The risk or severity of adverse effects can be increased when Treprostinil is combined with Azapropazone. Approved, Investigational Triamcinolone The risk or severity of adverse effects can be increased when Azapropazone is combined with Triamcinolone. Approved, Vet Approved Triamterene Azapropazone may decrease the antihypertensive activities of Triamterene. Approved Tribenoside The risk or severity of adverse effects can be increased when Azapropazone is combined with Tribenoside. Experimental Trichlormethiazide The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Azapropazone. Approved, Vet Approved Triptolide The risk or severity of adverse effects can be increased when Azapropazone is combined with Triptolide. Investigational Trolamine salicylate The risk or severity of adverse effects can be increased when Azapropazone is combined with Trolamine salicylate. Approved Trovafloxacin Azapropazone may increase the neuroexcitatory activities of Trovafloxacin. Approved, Investigational, Withdrawn Troxerutin Azapropazone may increase the anticoagulant activities of Troxerutin. Investigational Ulobetasol The risk or severity of adverse effects can be increased when Azapropazone is combined with Ulobetasol. Approved Unoprostone The therapeutic efficacy of Unoprostone can be decreased when used in combination with Azapropazone. Approved, Investigational Valdecoxib The risk or severity of adverse effects can be increased when Azapropazone is combined with Valdecoxib. Approved, Investigational, Withdrawn Valsartan The risk or severity of adverse effects can be increased when Valsartan is combined with Azapropazone. Approved, Investigational Vancomycin Azapropazone may decrease the excretion rate of Vancomycin which could result in a higher serum level. Approved Warfarin Azapropazone may increase the anticoagulant activities of Warfarin. Approved Ximelagatran Azapropazone may increase the anticoagulant activities of Ximelagatran. Approved, Investigational, Withdrawn Zaltoprofen The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Azapropazone. Approved, Investigational Zileuton The risk or severity of adverse effects can be increased when Zileuton is combined with Azapropazone. Approved, Investigational, Withdrawn Zofenopril The risk or severity of adverse effects can be increased when Azapropazone is combined with Zofenopril. Experimental Zoledronic acid The risk or severity of gastrointestinal bleeding can be increased when Azapropazone is combined with Zoledronic acid. Approved Zomepirac The risk or severity of adverse effects can be increased when Zomepirac is combined with Azapropazone. Withdrawn - Food Interactions
- Not Available
References
- Synthesis Reference
Molnar, I., Wagner-Jauregg,T., Jahn, U. and Mixich, G.; US. Patent 3,349,088; October 24, 1967; assigned to Siegfried AG, Switzerland Molnar, I.,Wagner-Jauregg,T., Jahn, U. and Mixich, G.; US. Patent 3,482,024; December 2, 1969; assigned to Siegfried AG.
- General References
- Not Available
- External Links
- ATC Codes
- M01AX04 — Azapropazone
- PDB Entries
- 2bx8 / 2bxi / 2bxk
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 187 Molnar, I., Wagner-Jauregg,T., Jahn, U. and Mixich, G.; US. Patent 3,349,088; October 24, 1967; assigned to Siegfried AG, Switzerland Molnar, I.,Wagner-Jauregg,T., Jahn, U. and Mixich, G.; US. Patent 3,482,024; December 2, 1969; assigned to Siegfried AG. - Predicted Properties
Property Value Source Water Solubility 0.641 mg/mL ALOGPS logP 0.92 ALOGPS logP 2.08 ChemAxon logS -2.7 ALOGPS pKa (Strongest Acidic) 0.52 ChemAxon pKa (Strongest Basic) 7.58 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 4 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 56.22 Å2 ChemAxon Rotatable Bond Count 2 ChemAxon Refractivity 85.69 m3·mol-1 ChemAxon Polarizability 31.94 Å3 ChemAxon Number of Rings 3 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 1.0 Blood Brain Barrier + 0.9389 Caco-2 permeable + 0.5728 P-glycoprotein substrate Non-substrate 0.5961 P-glycoprotein inhibitor I Inhibitor 0.8281 P-glycoprotein inhibitor II Inhibitor 0.6484 Renal organic cation transporter Non-inhibitor 0.7843 CYP450 2C9 substrate Non-substrate 0.8218 CYP450 2D6 substrate Non-substrate 0.8107 CYP450 3A4 substrate Substrate 0.6289 CYP450 1A2 substrate Inhibitor 0.5528 CYP450 2C9 inhibitor Non-inhibitor 0.8735 CYP450 2D6 inhibitor Non-inhibitor 0.9188 CYP450 2C19 inhibitor Non-inhibitor 0.8614 CYP450 3A4 inhibitor Non-inhibitor 0.8273 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.725 Ames test AMES toxic 0.5466 Carcinogenicity Non-carcinogens 0.8321 Biodegradation Not ready biodegradable 1.0 Rat acute toxicity 2.4784 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.7311 hERG inhibition (predictor II) Non-inhibitor 0.8171
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as aminotriazines. These are organic compounds containing an amino group attached to a triazine ring.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Triazines
- Sub Class
- Aminotriazines
- Direct Parent
- Aminotriazines
- Alternative Parents
- Pyrazolidinones / Benzenoids / 1,3-dicarbonyl compounds / 1,2,4-triazines / Guanidines / Carboxylic acid hydrazides / Propargyl-type 1,3-dipolar organic compounds / Azacyclic compounds / Organopnictogen compounds / Organic oxides show 1 more
- Substituents
- Amino-1,2,4-triazine / Aminotriazine / Pyrazolidinone / 1,3-dicarbonyl compound / Benzenoid / 1,2,4-triazine / Pyrazolidine / Carboxylic acid hydrazide / Guanidine / Azacycle show 12 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
Carriers
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Toxic substance binding
- Specific Function
- Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
- Gene Name
- ALB
- Uniprot ID
- P02768
- Uniprot Name
- Serum albumin
- Molecular Weight
- 69365.94 Da
References
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Drug created on September 15, 2010 15:21 / Updated on August 02, 2018 05:49